New lens for cataract surgery to improve vision

A Multi-center, Prospective, Randomized, Controlled Clinical Trial to Demonstrate the Safety and Effectiveness of the Full Visual Range AT ELANA 841P Posterior Chamber Intraocular Lens for Correction of Aphakia Following Cataract Removal

This study is testing a new type of lens for cataract surgery to see if it can help adults see better compared to a standard lens.

Quick facts

• Phase: Not applicable
• Study type: Interventional
• Enrollment: 286 (estimated)
• Ages: 22 Years to 100 Years
• Sex: All
• Sponsor: Carl Zeiss Meditec, Inc. (Industry-sponsored)
• Locations: 14 sites (Beverly Hills, California and 13 other locations)
• Trial ID: NCT06264232 on ClinicalTrials.gov

What this trial studies

This clinical trial aims to evaluate the safety and effectiveness of the AT ELANA 841P posterior chamber intraocular lens (IOL) in adult patients undergoing cataract surgery. Participants will be randomly assigned to receive either the investigational AT ELANA 841P trifocal IOL or the control CT LUCIA 621P monofocal IOL. The study will involve cataract surgery in both eyes, followed by a 6-month follow-up period during which patients will undergo eye exams and complete questionnaires about their vision quality. A total of 286 adults aged 22 and older will be enrolled across 14 clinical sites in the United States.

Who should consider this trial

Good fit: Ideal candidates are adults aged 22 years or older with cataracts and a best-corrected visual acuity of 20/40 or worse.

Not a fit: Patients with severe ocular conditions beyond cataracts or those with high astigmatism may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide patients with improved visual outcomes following cataract surgery.

How similar studies have performed: Other studies have shown success with similar intraocular lens approaches, indicating potential for positive outcomes.

Eligibility criteria

Inclusion Criteria:

1. Adults, 22 years of age or older at the time of study enrollment
2. Bilateral cataractous lens changes as demonstrated by best corrected distance visual acuity of 0.30 logMAR (20/40) or worse either with or without a glare source present (e.g., Brightness Acuity Tester) for which phacoemulsification cataract extraction and posterior chamber IOL implantation is indicated
3. Best corrected distance visual acuity projected to be better than 0.20 logMAR (better than 20/30) after cataract removal and IOL implantation
4. Preoperative keratometric (corneal) astigmatism of 1.00 D or less (≤1.00 D) in both operative eyes
5. Clear intraocular media other than cataract
6. Contact lens wear is to be discontinued two (2) weeks for soft contact lenses both daily and extended wear; and ≥ 30 days for rigid gas permeable lenses prior to preoperative biometry and keratometry testing.
7. Calculated lens power within the available range
8. Subject is willing to sign the IRB-approved informed consent form
9. Subject is willing, able and has sufficient cognitive awareness to comply with examination procedures and schedule for follow-up visits

Exclusion Criteria:

1. Presence of systemic disease that could increase the operative risk or confound the outcome, including but not limited to diabetes mellitus, active cancer treatment, mental illness, dementia, immunocompromised, connective tissue disease, clinically significant atopic disease, etc.
2. Ocular condition that may predispose for future complications, including but not limited to dry eye syndromes or symptoms, anterior segment pathology, glaucoma (uncontrolled despite intake of medication), history of cystoid macular edema, macular degeneration as confirmed by clinical examination and adjunct testing (e.g., OCT, FA)
3. Clinically significant corneal abnormalities, including corneal dystrophy (epithelial, stromal or endothelial dystrophy), irregularity, inflammation or edema; conditions including but not limited to active/inactive keratitis, keratoconjunctivitis, kerato uveitis, keratopathy, keratectasia
4. Previous intraocular or corneal surgery that might confound the outcome of the investigation or increase the risk to the subject, including corneal transplants, retinal detachment, glaucoma surgeries, refractive laser procedures including but not limited to LASIK, limbal relaxing incision, Small Incision Lenticule Extraction (SMILE) etc.
5. Use of or history of use of systemic medications with significant ocular side effects or any medications that could confound the outcome or increase subject risk (e.g., Tamsulosin Hydrochloride \[Flomax\] or other medications including anticholinergics or alpha-adrenergic blocking agents with similar side effects \[e.g., small pupil/floppy iris syndrome\], antimetabolites, etc.)
6. Currently taking systemic steroids and/or planned on taking systemic steroids prior to operative visit and during the course of the investigation.
7. Subjects with diagnosed degenerative visual disorders, including but not limited to macular degeneration or other retinal disorders (such as diabetic retinopathy, diabetic macular edema, retinal detachment) that are predicted to confound outcomes or to cause future acuity loss to 0.20 logMAR or worse.
8. Subjects with conditions that increase the risk of zonular rupture (e.g., pseudoexfoliation syndrome, Marfan's syndrome) during cataract extraction procedure that may affect the postoperative centration or tilt of the IOL
9. Expected concomitant ocular procedure during cataract surgery or within the next 12 months (e.g., glaucoma surgery including implantation of MIGS, astigmatic correction surgery, penetrating keratoplasty \[PK\], laser-assisted in situ keratomileusis, SMILE etc.)
10. Subjects who are expected to require retinal laser treatment within the next 12 months
11. History of amblyopia or monofixation syndrome with poor stereoscopic vision
12. Rubella, congenital, traumatic or complicated cataracts
13. History of or current anterior or posterior segment inflammation, including but not limited to iritis or uveitis
14. Microphthalmos or macrophthalmos
15. Iris defects (e.g., aniridia)
16. Optic nerve atrophy
17. Keratoconus or Irregular astigmatism, as determined by topography
18. Inability to perform keratometry, topography or biometry (including but not limited to cataract density, subject unable to focus for longer time etc.) or subjects with unstable keratometry, topography or biometry measurements
19. Pathologic miosis caused by anterior segment pathology in the study eye (e.g., chronic uveitis, iritis, rubeosis iridis, neurological conditions such as multiple sclerosis, Argyle Robertson's pupil, acquired or congenital Horner´s syndrome, etc.)
20. Pupil diameter less than 6 mm when fully dilated
21. Pregnant, lactating at time of enrollment, or has another condition with associated fluctuation of hormones that could lead to refractive changes
22. Subject whose freedom is impaired by administrative or legal order
23. Concurrent participation in another drug or device investigation that could confound the outcome of this investigation
24. Subjects unable to achieve keratometry stability after discontinuing contact lens wear
25. Gonioscopic abnormalities

Where this trial is running

Beverly Hills, California and 13 other locations

• Beverly Hills Institute of Ophthalmology — Beverly Hills, California, United States (Recruiting)
• Mitchell C Shultz MD/Shultz Chang Vision — Northridge, California, United States (Recruiting)
• Coastal Vision Medical Group — Orange, California, United States (Recruiting)
• Cape Coral Eye Center — Cape Coral, Florida, United States (Recruiting)
• Chu Vision Institute — Bloomington, Minnesota, United States (Recruiting)
• Ophthalmology Consultants of St Louis — Saint Louis, Missouri, United States (Recruiting)
• Vance Thompson Vision-Nebraska — Omaha, Nebraska, United States (Recruiting)
• Cleveland Eye Clinic — Brecksville, Ohio, United States (Recruiting)
• Carolina Eyecare Physicians, LLC — Mount Pleasant, South Carolina, United States (Recruiting)
• Vance Thompson Vision-South Dakota — Sioux Falls, South Dakota, United States (Recruiting)
• Whitsett Vision Group — Houston, Texas, United States (Recruiting)
• Texas Eye & Laser — Hurst, Texas, United States (Recruiting)
• PNV Clinical Research — San Antonio, Texas, United States (Recruiting)
• Eye Centers of Racine & Kenosha — Kenosha, Wisconsin, United States (Recruiting)

Study contacts

• Principal investigator: Seth M Pantanelli, MD — Penn State Health
• Study coordinator: Mr. Eric Schorsch, MS

Conditions Cataract Senile; Cataract; Cataract Surgery